About the Project
Outcomes relevant to breast cancer radiotherapy trials
As for any medical treatment, radiotherapy for breast cancer has to balance clinical benefit in terms of treating the cancer against minimising treatment-related adverse effects. Hence important outcomes in breast cancer radiotherapy trials include disease-related efficacy outcomes, i.e. recurrence and survival, as well as radiotherapy-related adverse effects. These radiotherapy adverse effects are usually termed “normal tissue effects” (NTE) as they relate to the healthy normal tissues that may receive some radiation dose when the area around where the tumour site is treated. These normal tissue effects can occur in the short-term (during and shortly after radiotherapy) and tend to resolve quickly, but long-term effects can occur up to many years following radiotherapy. Although rates of these so-called late normal tissue effects have declined following developments in radiotherapy techniques, they remain prevalent (around 25% may experience a moderate/marked adverse effect in the treated breast by 5 years following radiotherapy), and can be permanent (e.g. breast shrinkage), potentially having a long-term impact on patients. Severe radiotherapy-related adverse effects such as cardiac or lung disease are rare, but clearly clinically important. In the era of very low disease event rates (around 2% of patients experience a recurrence of the cancer in their breast within 5 years) it is even more imperative to minimise treatment-related adverse effects, and hence appropriate measurement of these effects within clinical trials is essential.
For details on how to apply using our online recruitment portal please see icr.ac.uk/phds. Please note we only accept applications via the online application system apply.icr.ac.uk
First, or, upper-second class honours degree (or equivalent) in a relevant subject.
A masters degree in a relevant subject.
Successful candidates will undertake a three-year research training programme under the guidance of a supervisory team of our world-class researchers, starting in January 2021 unless otherwise specified. Students will receive an annual stipend, currently £21,000 per annum, as well as having fees and project costs paid for the three-year duration.
We particularly welcome applicants from British Black and ethnic minority backgrounds, as they are under-represented at PhD level within the ICR and nationwide.
Based on your current searches we recommend the following search filters.
Based on your current search criteria we thought you might be interested in these.